Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Patterson

Showing results (1131-1140 of 1,160) with videos related to

Pageof 116
Sort By:
Investigative Ophthalmology & Visual Science|July 23, 2016
Cone Photoreceptor Structure in Patients With X-Linked Cone Dysfunction and Red-Green Color Vision DeficiencyEmily J Patterson, Melissa Wilk, Christopher S Langlo, et al.
Journal of the American College of Cardiology|May 30, 2009
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid diseaseTjun Y Tang, Simon P S Howarth, Sam R Miller, et al.
Retina (Philadelphia, Pa.)|February 2, 2017
REPEATABILITY AND LONGITUDINAL ASSESSMENT OF FOVEAL CONE STRUCTURE IN CNGB3-ASSOCIATED ACHROMATOPSIAChristopher S Langlo, Laura R Erker, Maria Parker, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
Molecular Psychiatry|November 17, 2004
Support for involvement of neuregulin 1 in schizophrenia pathophysiologyT L Petryshen, F A Middleton, A Kirby, et al.
Journal of the Advanced Practitioner in Oncology|October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center ExperienceFedricker D Barber, Erick Campbell, Yuko Yamamura, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Pageof 116

Showing results (1131-1140 of 1,160) with videos related to

Sort By:
Pageof 116
Investigative Ophthalmology & Visual Science|July 23, 2016
Cone Photoreceptor Structure in Patients With X-Linked Cone Dysfunction and Red-Green Color Vision DeficiencyEmily J Patterson, Melissa Wilk, Christopher S Langlo, et al.
Journal of the American College of Cardiology|May 30, 2009
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid diseaseTjun Y Tang, Simon P S Howarth, Sam R Miller, et al.
Retina (Philadelphia, Pa.)|February 2, 2017
REPEATABILITY AND LONGITUDINAL ASSESSMENT OF FOVEAL CONE STRUCTURE IN CNGB3-ASSOCIATED ACHROMATOPSIAChristopher S Langlo, Laura R Erker, Maria Parker, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
Molecular Psychiatry|November 17, 2004
Support for involvement of neuregulin 1 in schizophrenia pathophysiologyT L Petryshen, F A Middleton, A Kirby, et al.
Journal of the Advanced Practitioner in Oncology|October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center ExperienceFedricker D Barber, Erick Campbell, Yuko Yamamura, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Pageof 116